# Lupeol‐Loaded Liposomes: Triple‐Negative Breast Cancer (TNBC) Cytotoxicity and In Vivo Toxicological Evaluation

## TL;DR

Researchers developed a liposomal formulation of lupeol, a natural compound, which shows promise in fighting triple-negative breast cancer without significant toxicity in mice.

## Contribution

The study introduces a liposomal delivery system for lupeol that enhances its therapeutic potential against triple-negative breast cancer.

## Key findings

- The liposomal lupeol formulation showed cytotoxic, cytostatic, and apoptotic effects on MDA-MB-231 cancer cells.
- In vivo tests showed no significant toxicity in healthy mice.
- The formulation improves lupeol's bioavailability for potential therapeutic use.

## Abstract

Lupeol is a natural product commonly found in many vegetables and fruits in significant quantities. Previous studies have demonstrated the relevant activity of lupeol against various tumor cell lines, suggesting that the natural product could be a promising agent for cancer treatment. Due to bioavailability requirements, lupeol presents a challenge for internal administration in therapeutic doses. Thus, the development of pharmaceutical formulations, particularly nanostructured systems, could represent an important alternative to improving the bioavailability of the molecule. This study developed and characterized a liposomal formulation loaded with lupeol, exhibiting substantial cytotoxic, cytostatic, and apoptotic profiles against the MDA‐MB‐231 tumor cells, a triple‐negative human breast cancer subtype. Toxicological in vivo evaluations revealed a nonrelevant toxic profile against healthy mice. Considering all the results obtained, the present study revealed important potentialities of the liposomal system, constituting a potential therapeutic alternative against triple‐negative breast cancer.